Ranbaxy – Daiichi Sankyo Deal Akash Bangani Dipika Bhura Gaurav Khetan Neetu Rathod 12065 12077 12082 12118 Agenda • • • • • • • • • • Industry Overview Companies’ Profiles Snapshot of the deal Financing the deal Benefits to Daiichi Benefits to Ranbaxy Synergies Post Acquisition challenges Recent Developments Conclusion Indian Pharmaceutical Industry • Present size of $14 billion. • Ranks 4th in world in terms of production and 13th in terms of consumption. • Highly fragmented. 325 large
Premium Generic drug Pharmaceutical industry 3rd millennium
11 Title Introduction Background of Ranbaxy Brief History Market share of Ranbaxy Background of Daiichi Sankyo Brief History Market share of Daiichi Sankyo SPOT Analysis of the Indian Pharma Industry Resaons for the Deal Why Ranbaxy did it Why Daiichi Sankyo did it Disadvantages of the deal The Deal Shareholding Pattern Interpretation of the Shareholding pattern Financing the Deal Effects of the Acquisition Benefits for Ranbaxy Benefits for Daiichi Sankyo Benefits for the combined company Impact
Premium Pharmaceutical industry Generic drug
A REPORT ON Ranbaxy-Daiichi Deal 1/26/2012 Ranbaxy-Daiichi Deal Introduction: Daiichi Sankyo bought Ranbaxy for $4.6 billion in June 2008. This report studies the implications of the merger between Ranbaxy and Daiichi Sankyo‚ from an intellectual property as well as a market point of view. There are many critical events happening in international pharma market including the growing preference for generics‚ increasing dominance of emerging markets such as India‚ fast approaching patent expiry
Premium Generic drug Ranbaxy Laboratories Pharmaceutical industry
Ranbaxy Laboratories Limited (Ranbaxy) is a research based international pharmaceutical company serving customers in over 150 countries. The company was incorporated in 1961 and it went public in 1973.In 1998 Ranbaxy entered the United States which is the largest pharmaceutical market. In 2008 Daiichi Sankyo a leading pharmaceutical innovator‚ headquartered in Tokyo‚ Japan acquired a controlling share in the company. Ranbaxy produces a wide range
Premium Generic drug Pharmaceutical industry Ranbaxy Laboratories
| Ranbaxy Laboratories Ltd. | | "Personally‚ I feel that companies who constantly innovate to provide better products and services and who can offer superior value propositions to the consumer are the ones likely to command more respect globally than others” Malvinder Mohan Singh‚ former CEO and MD‚ Ranbaxy Laboratories Ltd Table of Contents Executive Summary 5 The Company 5 Hybrid Business Model 6 Porter’s Five Force Analysis 7 Bargaining Power of Buyers 8 Bargaining
Premium Generic drug Pharmaceutical industry Ranbaxy Laboratories
Metrics Used to Measure Training Impact At Ranbaxy L.N.D. Report Compiled By: Group 5 Aditi Chahana Nayan Prasun Priyam Under the Guidance of Prof. A. U. Bhaskar Acknowledgement All of us together have put in constant efforts in the making of this report. However‚ it would not have been successful without the kind support‚ help and guidance of all our mentors. We would like to extend our sincere thanks to all of them without which this would not have been possible. We are
Premium Ranbaxy Laboratories Skill Donald Kirkpatrick
to the Daiiichi - Ranbaxy acquisition RANBAXY LABORATORIES LIMITED Ranbaxy Laboratories Limited‚ India’s largest pharmaceutical company‚ was an integrated‚ research based‚ international pharmaceutical company producing a wide range of quality‚ affordable generic medicines‚ trusted by healthcare professionals and patients across geographies. It was incorporated in 1961 by Singh’s grandfather Bhai Mohan Singh‚ further his son Dr. Parvinder Singh succeeded it‚ transforming Ranbaxy into India’s first
Premium Generic drug Ranbaxy Laboratories
Limited’s (Ranbaxy) profile as a pharmaceutical company underwent a sea change during the period 1985-1995. During this period Ranbaxy diversified into different products‚ markets and in general over the ‘value curve’. Its export sales grew from 7.45% of total sales in 1985 to 42.4% of total sales 1995. The growth in the foreign markets was primarily led by bulk drugs and intermediates‚ which constituted 80% of the foreign sales in 1995. Driven by the vision of CEO Parvinder Singh‚ Ranbaxy had consciously
Free Developed country Developing country Emerging markets
(8NBNG169) A Thesis on “TO STUDY PROMOTIONAL STRATEGY ADOPTED BY RANBAXY LABORATORIES LTD RELATED TO RANITIDINE-150mg (Antiulcerant) IN NAGPUR CITY” INTRODUCTION OBJECTIVES:- To study the overview of Indian Pharmaceutical Market. To study the culture of Ranbaxy Lab. To find out the promotional strategies used by Ranbaxy with respect to ‘Histac’ tab. To find out various promotional strategies used by Ranbaxy to acquire market share in Nagpur city. To study the competitors of
Premium Generic drug Pharmaceutical industry Gastroesophageal reflux disease
Geerte Hofstede analysis Globalization is nowadays evidential in nearly every aspect of life. It can be shortly described “as the world is getting smaller”[1]. “The term describes the growing political‚ social‚ cultural‚ economic and technological interconnectedness and interdependence of the world today. As communication technologies advance‚ cultures continue to overlap and influence each other.”[2] What are the differences especially in cultural dimensions in countries like Germany and the United
Premium Cross-cultural communication United States United Kingdom